# Oncopeptides

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncopeptides

- Industry: Pharmaceuticals
- Headquarters: Stockholm, Sweden
- Website: www.oncopeptides.se
- Latest round: Series A (May 21, 2013)
- Investors on record: 2

## About

Founded in 2000 and based in Stockholm, Sweden, Oncopeptides AB operates as a pharmaceutical company that develops anti-cancer drug research as treatments for cancer patients. In November 2021, Oncopeptides AB raised EUR 30 million in venture debt funding from investor European Investment Bank.


The company offers anti-cancer drugs for cancer treatment such as "Melflufen", a cancer treatment for hematological cancers developed by Dr. Joachim Gullbo at Uppsala University collaborated with the Harvard Medical School and Dana Farber of Cancer Institute.

Oncopeptides AB's revenue is generated from developing drugs specifically for cancer patients.

## Funding rounds

- Series A, May 21, 2013 — Industrifonden, HealthCap

## Investors

- Industrifonden (https://capitalatlas.ai/funds/industrifonden) — Series A
- HealthCap — Series A